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Background. Microarray technology enables a standardized, objective assessment of oncological diagnosis and prognosis.
However, such studies are typically specific to certain cancer types, and the results have limited use due to inadequate
validation in large patient cohorts. Discovery of genes commonly regulated in cancer may have an important implication in
understanding the common molecular mechanism of cancer. Methods and Findings. We described an integrated gene-
expression analysis of 2,186 samples from 39 studies to identify and validate a cancer type-independent gene signature that
can identify cancer patients for a wide variety of human malignancies. The commonness of gene expression in 20 types of
common cancer was assessed in 20 training datasets. The discriminative power of a signature defined by these common cancer
genes was evaluated in the other 19 independent datasets including novel cancer types. QRT-PCR and tissue microarray were
used to validate commonly regulated genes in multiple cancer types. We identified 187 genes dysregulated in nearly all
cancerous tissue samples. The 187-gene signature can robustly predict cancer versus normal status for a wide variety of human
malignancies with an overall accuracy of 92.6%. We further refined our signature to 28 genes confirmed by QRT-PCR. The
refined signature still achieved 80% accuracy of classifying samples from mixed cancer types. This signature performs well in
the prediction of novel cancer types that were not represented in training datasets. We also identified three biological
pathways including glycolysis, cell cycle checkpoint II and plk3 pathways in which most genes are systematically up-regulated
in many types of cancer. Conclusions. The identified signature has captured essential transcriptional features of neoplastic
transformation and progression in general. These findings will help to elucidate the common molecular mechanism of cancer,
and provide new insights into cancer diagnostics, prognostics and therapy.
Citation: Lu Y, Yi Y, Liu P, Wen W, James M, et al (2007) Common Human Cancer Genes Discovered by Integrated Gene-Expression Analysis. PLoS
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INTRODUCTION
Cancer is one of the leading causes of death in Western countries
resulting in one of every four deaths. More than 100 types of
cancer with different incidence have been diagnosed in various
organs or tissues. Cancer is associated with multiple genetic and
regulatory aberrations in the cell. To capture these abnormalities,
DNA microarrays, which permit the simultaneous measurement of
expression levels of tens of thousands of genes, have been
increasingly utilized to characterize the global gene-expression
profiles of tumor cells and matched normal cells of the same
origin. Over the past years, the global gene-expression profiles of
various cancers have been analyzed and many gene-expression
signatures that are associated with cancer progression, prognosis
and response to therapy have been described [1–19]. However,
such studies are typically specific to certain tumors. The cancer
type-specific signatures from these studies show little overlap in
gene constitutions and biologically important pathways. Decades
of research in molecular oncology have yielded few useful tumor-
specific molecular markers, due to limitations with sample
availability, identification, acquisition, integrity, and preparation
[20]. Cancer is a highly heterogeneous disease, both morpholog-
ically and genetically. It remains a challenge to capture an
essential, common transcriptional feature of neoplastic trans-
formation and progression.
To extract maximum value from the recent accumulation of
publicly available cancer gene-expression data, it is necessary to
evaluate, integrate and inter-validate multiple datasets. Compre-
hensive analyses of a myriad of published datasets make it possible
to find common cancer genes and essential functional conse-
quences that are associated with tumor initiation and progression
in general. Systematic characterization of expression changes in
biological pathways among different types of cancer will eventually
lead to a better understanding of which perturbations in the cell
give rise to cancer. These findings will provide multiple clinical
directions for cancer diagnostics, prognostics and therapy on the
basis of the gene expression signature of patients. In the present
study, we described an integrated gene-expression analysis of
2,186 samples from 39 different studies to identify and validate
a cancer gene signature that is independent of tumor types and can
identify cancer patients for a wide variety of human malignancies.
RESULTS
Common gene expression changes in various cancer
types
We first analyzed gene expression profiles of 1,223 human samples
(343 normal tissues and 880 tumor tissues) from the training
datasets 1–20 containing 20 different types of cancers (Table S1).
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statistically assessed by permutation analyses (p,10
25). In total,
187 genes commonly affected in cancer were identified. Of these,
117 were up-regulated and 70 were down-regulated in nearly all
cancerous tissue samples, regardless of their tissue of origin
(Table 1 and 2). With the bioinformatics tool, FatiGO (http://
fatigo.bioinfo.cnio.es), we found 142 out of 187 cancer genes were
significantly associated with at least one Gene Ontology (GO)
category. Several functional categories have been shown to be
important for carcinogenesis and cancer progression (Table S2).
For example, 11 genes (BFAR, CARD4, SPP1, SNCA, BAX,
STAT1, CLU, GULP1, BID, CIDEA and PPP2R1B) control
programmed cell death; 8 genes (TTK, RECK, BAX, STAT1,
NME1, CCNB2, E2F3 and PPP2R1B) are involved in regulation
of the cell cycle; 8 genes (TAP1, APOL2, SPP1, CLU, PSMB8,
TAPBP, HLA-F and TNFSF13B) play roles in the immune
response; and 6 genes (TTK, SPP1, NME1, NAP1L1, NPM1 and
TNFSF13B) regulate cell proliferation. In addition, genes that are
involved in protein transport, M phase cell cycle, secretory
pathway and DNA repair are consistently up-regulated in a large
majority of cancer types.
Validation of common cancer genes by QRT-PCR and
TMA
To validate the microarray gene expression results from the
integrated gene-expression analysis, the relative expression levels of
32 of the 187 cancer genes were determined by QRT-PCR analysis
using completely independent samples from three each of breast,
lung, prostate, colon and cervical cancer and their matched normal
tissue. We confirmed the expression results for most of these selected
genes (fold change .1.5, p#0.05 and consistency .60%) (Table3).
The top 10 genes with absolute fold change .4, p#0.05 and
consistency .85% were further confirmed using another 18
matched tumor and normal samples from breast, lung and cervical
cancer patients. In the expanded analysis, the expression levels of
these 10 genes were still significantly different with absolute fold
change .4, p#0.05 and consistency .85%, except genes SPP1 and
NDRG2, which exhibited slightly decreased consistency (Figure 1).
Tissue microarray analysis (TMA) was also performed for three
randomly picked common cancer genes (SPP1, BID and CLU) to
determine if mRNA changes were correlated with changes in
protein expression in cancer patients. The tissue microarray
contains 200 tumor samples with 50 samples from each of four
cancer types (colon, breast, ovarian, and lung). Analysis of SPP1
protein expression in tumor and normal tissues indicated that
SPP1 is present in the cytoplasm and nucleus of cells. Most
samples from colon adenocarcinoma, breast adenocarcinoma,
ovary adenocarcinoma, and lung cancer showed intermediate to
strong cytoplasmic SPP1 staining in tumor cells, but the staining in
normal tissues was much weaker. The average scores for tumor
and normal tissues are 11.161.8 and 1.861.5 in colon
adenocarcinoma (p=0.0005), 10.961.7 and 4.563.8 in breast
adenocarcinoma (p=0.043), 11.761.0 and 3.364.2 in ovary
adenocarcinoma (p=0.028), and 9.062.2 and 3.562.0 in lung
cancer (p=0.0005), respectively (Figure 2 and Figure S1).
Positive cytoplasmic staining of clusterin (CLU) was present on
both tumor and normal cells in lung, breast, and ovary tissue.
However, as compared with normal tissues, the clusterin decreased
in lung cancer (5.662.1 vs. 10.861.6, p=0.005), breast cancer
(7.162.7 vs. 10.561.7, p=0.017), and ovarian cancer (6.863.0 vs.
10.561.7, p=0.011) (Figure 3A, B and D). Colon cancer
showed much less positive CLU staining than other types of tumor
and there was no significant difference between colon tumor and
normal colon tissues (Figure 3C). BID protein was significantly
upregulated in colon cancer, lung cancer and breast cancer, but
not in ovarian cancer (data not shown). The average scores of
immunoreactive staining in tumor and normal tissues are
11.261.9 vs. 2.061.4 (p=0.00015), 10.462.2 vs. 2.562.2
(p=0.0002) and 11.561.4 vs. 6.561.9 (p=0.010) for these three
cancer types, respectively (Figure 3E–G). Semiquantitative
analysis indicates that most of samples from different types of
cancer have strong, high percentage of BID immunoreaction,
while normal tissues only show low to medium level of staining;
CLU tends to be down-regulated in tumors (Figure 3H). The
results demonstrate that protein level is largely consistent with the
mRNA expression of these three genes.
Common cancer pathways in various cancer types
We further surveyed a listing of 1,687 biological pathways which
include metabolic pathways, protein interaction networks, signal
transduction pathways, and gene regulatory networks to examine if
several genes within a specific pathway act in a cumulative manner
to influence neoplastic transformation and progression. The richness
of significantly differentially expressed genes in a given pathway was
again evaluated by 100,000 permutation tests in the training
datasets. Pathway analysis showed that significant differentially
expressed genes (p,0.01) were mostly enriched in the glycolysis
pathway, cell cycle checkpoint II pathway and plk3 pathway, which
included 24, 10 and 10 genes, respectively (p,10
25). Interestingly,
most of the genes involved in these three pathways are up-regulated
in a large majority of cancerous tissues as compared with normal
tissues (Figure S2), suggesting the prevalence of gene hyperactiva-
tion and amplification in human malignancies.
Confirmation of the common gene expression
pattern in independent datasets
Next, we determined to validate our gene expression signature and
see if we could distinguish cancer samples from normal samples in
completely independent datasets. The discriminative power of the
187-gene expression signature in normal and tumor samples was
tested by clustering analysis using oligonucleotide gene expression
data obtained from 19 completely independent datasets. Datasets
21 to 38, used for validation, were comprised of 211 normal and
492 tumor tissues from 14 different cancer types. In most of these
18 datasets, samples were classified into two groups, one
comprising of most normal samples and another for most tumor
samples, based on our 187 gene signature (Figure S3). The
overall accuracy of correct classification is, on average, 92.64%
ranging from 78% to 100% (Table 4). It should be noted that
dataset 30 and 31 are slightly different from the other datasets due
to heterogeneity of cancer samples. All the samples in these two
datasets were classified into two big groups: one containing tumor
samples only; the other group containing both tumors and
normals, which can be clearly distinguished as two subgroups.
Specifically, in dataset 30, eight myeloma cell lines formed one
group with inclusion of one plasma cell leukemia (PCL); in the
other group, eight normal plasma cell samples and eight samples
from patients with multiple myeloma (MM) or PCL were clearly
subdivided. In dataset 31, six metastatic prostate cancer samples
were grouped together, while normal tissues and primary prostate
cancers were in the other group, with six normal tissues and one
primary prostate cancer in one subgroup, and six primary prostate
cancers in the other subgroup. In clustering analysis for tumor
samples of different subtypes with gene expression data, it is not
unusual that some tumor subgroups are closer to the normal
group, but are clearly distinguished from the normal group.
Common Genes in Human Cancers
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..................................................................................................................................................
UniGene Gene symbol N Up # Down # UniGene Gene symbol N Up # Down #
Hs.159430 FNDC3B 11 10 0 Hs.239388 PAQR8 8 5 1
Hs.518201 DTX3L 8 7 0 Hs.592827 RBAK 8 5 1
Hs.530899 LOC162073 8 7 0 Hs.525157 TNFSF13B 8 5 1
Hs.15159 CKLF 11 9 1 Hs.126774 DTL 13 8 0
Hs.474150 BID 16 13 0 Hs.385913 ANP32E 13 8 1
Hs.7753 CALU 15 12 0 Hs.532968 DKFZp762E1312 13 8 1
Hs.418795 GLT25D1 10 8 0 Hs.372429 PDIA6 13 8 1
Hs.435556 BFAR 12 9 0 Hs.233952 PSMA7 13 8 1
Hs.459362 PRC1 12 9 1 Hs.533770 SLC38A1 13 8 1
Hs.521800 C8orf76 8 6 0 Hs.489284 ARPC1B 18 11 0
Hs.209561 KIAA1715 8 6 0 Hs.497788 EPRS 18 11 0
Hs.585011 C1orf96 8 6 1 Hs.79110 NCL 18 11 0
Hs.403933 FBXO32 8 6 1 Hs.251531 PSMA4 18 11 0
Hs.368853 AYTL2 15 11 1 Hs.429180 EIF2S2 18 11 1
Hs.511093 NUSAP1 11 8 0 Hs.465885 ILF3 18 11 1
Hs.370895 RPN2 14 10 0 Hs.169840 TTK 18 11 1
Hs.180062 PSMB8 17 12 0 Hs.489365 AP1S1 15 9 1
Hs.444600 BOLA2 10 7 0 Hs.256639 PPIH 15 9 1
Hs.445890 CNIH4 13 9 0 Hs.14559 CEP55 10 6 1
Hs.534392 KDELR3 13 9 0 Hs.308613 MTERFD1 10 6 1
Hs.632191 XTP3TPA 13 9 0 Hs.21331 ZWILCH 10 6 1
Hs.387567 ACLY 19 13 1 Hs.524599 NAP1L1 17 10 1
Hs.533282 NONO 18 12 0 Hs.78771 PGK1 17 10 2
Hs.83753 SNRPB 18 12 0 Hs.512380 PLEKHB2 12 7 1
Hs.471441 PSMB2 18 12 1 Hs.352018 TAP1 19 11 1
Hs.482497 TNPO1 18 12 1 Hs.194698 CCNB2 14 8 1
Hs.370937 TAPBP 15 10 0 Hs.153357 PLOD3 14 8 1
Hs.126941 FAM49B 12 8 0 Hs.471200 NRP2 14 8 2
Hs.408629 KDELC1 12 8 0 Hs.250822 AURKA 16 9 1
Hs.497384 IPO9 12 8 1 Hs.75528 GNL2 16 9 1
Hs.8752 TMEM4 12 8 1 Hs.1197 HSPE1 16 9 1
Hs.195642 C17orf27 9 6 0 Hs.202672 DNMT1 18 10 1
Hs.358997 TTL 9 6 0 Hs.433670 FTL 18 10 1
Hs.1600 CCT5 20 13 0 Hs.519972 HLA-F 18 10 1
Hs.269408 E2F3 17 11 0 Hs.520210 KDELR2 18 10 1
Hs.234027 ZBTB12 17 11 1 Hs.405153 CARD4 11 6 1
Hs.520205 EIF2AK1 14 9 0 Hs.477700 DBR1 11 6 1
Hs.89545 PSMB4 14 9 0 Hs.14468 FLJ11286 11 6 1
Hs.449415 EIF2C2 14 9 1 Hs.516077 FLJ14668 11 6 1
Hs.409065 FEN1 14 9 1 Hs.494337 GOLPH2 11 6 1
Hs.313 SPP1 14 9 1 Hs.371036 NOX4 11 6 1
Hs.525135 FARP1 14 9 2 Hs.438683 SLAMF8 11 6 1
Hs.524390 K-ALPHA-1 11 7 0 Hs.520714 SNX10 11 6 1
Hs.432360 SCNM1 11 7 0 Hs.159428 BAX 13 7 1
Hs.172028 ADAM10 19 12 0 Hs.311609 DDX39 13 7 1
Hs.381189 CBX3 19 12 0 Hs.463035 FKBP10 13 7 1
Hs.522257 HNRPK 19 12 0 Hs.438695 FKBP11 13 7 1
Hs.470943 STAT1 19 12 0 Hs.515255 LSM4 13 7 1
Hs.118638 NME1 19 12 1 Hs.552585 MORC2 13 7 1
Hs.519452 NPM1 19 12 1 Hs.43666 PTP4A3 13 7 1
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Common Genes in Human Cancers
PLoS ONE | www.plosone.org 3 November 2007 | Issue 11 | e1149Dataset 39 included 180 tumor samples, spanning 14 common
tumor types, and 81 normal tissue samples. Among 14 tumor
types, uterine adenocarcinoma, leukemia and pleural mesotheli-
oma were not present in the 20 training datasets. In clustering
analyses, samples are clustered into three groups: tumor group I
composing of 57 tumors and 20 normal tissues, normal group
composing of 11 tumors and 53 normal tissues, and tumor group
II composing of 112 tumor and 8 normal tissues (Figure 4). The
accuracy of classification is 85%. All of central nervous system
cancer and most of pancreatic adenocarcinoma were classified into
tumor group I, while all of leukemia and most of lymphomas were
classified into tumor group II. Notably, the 187-gene signature
performs well (81–100%) in classifying new cancer types (such as
uterine adenocarcinoma, leukemia and pleural mesothelioma). It is
also worth noting that there only ,31–60% of genes from this 187
gene signature that were used in clustering analyses in each of
validation datasets due to the specificity of platforms, sample
availability and missing values in microarray experiments.
Furthermore, the set of genes used for clustering analyses are in
part different among validation datasets, depending on the
availability of gene-expression data in a specific study. This
demonstrated the robustness, utility and ubiquity of our gene
signature. Lastly, we also attempted to classify these 261 samples
using the expression profiles of 28 common cancer genes
confirmed by the QRT-PCR analysis with fold change .3 and
consistency .60%. The refined 28-gene signature still achieved
,80% accuracy of classification (Figure S4). It should be noted
that dataset 39 used an old microarray system of Affymetrix FL
6800 gene chip with a total of 7,289 probes. The numbers of
probes used in the above two clustering analyses for the dataset 39
were 72 and 19, corresponding to 59 and 15 genes, respectively.
DISCUSSION
DNA microarray-based gene-expression classification enables
a standardized, objective assessment of oncological diagnosis and
prognosis and provides complementary information to current
clinical protocols [20]. However, such studies are typically specific
to certain types of cancer, and the obtained expression profiles
have limited use due to inadequate validation in large patient
cohorts. In this study, we identified a gene signature for molecular
cancer classification through an integrative gene-expression
analysis of 20 different types of common cancer. This signature
contains 187 genes whose aberrant expression was observed in
nearly all cancerous tissue samples, regardless of their tissue of
origin. To illustrate the utility and robustness of this signature, we
determined its discriminative power on another 19 completely
independent datasets. The accuracy of classification is about
92.6% by using this common cancer signature. Interestingly,
a different subset of genes that account for 31–60% of the 187-
gene signature can rigorously identify cancer patients for a wide
variety of human malignancies. More importantly, this signature
also performs well in the prediction of novel cancer types that were
not represented in the integrative analysis in training datasets. This
confirms that the identified signature is cancer type-independent
and has captured certain of the essential transcriptional features of
neoplastic transformation and progression in general. However, it
remains unknown whether all of these genes in our signature are
involved in the development of cancer. Some of them may be an
indication of something going on in the body that is accompanying
the disease process; while others are genes pe se that promote
tumorigenesis and cancer progression. We also compared our
signature with two other signatures in independent datasets that
were previously used in those studies [21,22]. The overall accuracy
of correct classification using our signature is, on average, 95%
ranging from 90% to 100%; while the overall accuracy of Rhode’s
and Xu’s is 89% and 93%, respectively (Table S3). The two
previous signatures were determined either from the same set of
genes in a single microarray platform [21] or common genes
among different platforms [22]. The analyzed genes only represent
a subset of genes on the genome (about 25%) and were highly
over-represented in their signatures; while the other genes that are
not presented in the analyzed platform or are not common among
platforms were missed in their signatures. In the present study, the
proposed method for determining gene signature is straightfor-
ward and independent of different microarray platforms (for
example various uncommercial cDNA chips and Affymetrix
chips). Therefore, we can utilize information of all the genes in
a specific microarray study. Our study also highlights the
importance of the large sample size in microarray analyses for
identifying and validating prognostic signatures. In this study, we
pooled a total of 2,186 samples from 39 independent microarray
studies for classifier discovery and validation. The results from this
large-scale integrative gene-expression analysis should be more
robust and reliable than each of potentially under-powered
individual studies.
We also identified several common pathways where altered
expression of several genes act in a common pathway to influence
tumor development. These pathways include the glycolysis, cell
Table 1. cont.
..................................................................................................................................................
UniGene Gene symbol N Up # Down # UniGene Gene symbol N Up # Down #
Hs.506748 HDGF 16 10 0 Hs.369440 SFXN1 13 7 1
Hs.386283 ADAM12 16 10 2 Hs.517155 TMEPAI 13 7 1
Hs.474740 APOL2 8 5 0 Hs.631580 UBA2 13 7 1
Hs.552608 C1orf58 8 5 0 Hs.463465 UTP18 13 7 1
Hs.470654 CDCA7 8 5 0 Hs.492974 WISP1 13 7 1
Hs.179838 FMNL3 8 5 0 Hs.113876 WHSC1 13 7 2
Hs.143818 GEMIN6 8 5 0 Hs.494614 BAT2D1 15 8 2
Hs.6459 GPR172A 8 5 0 Hs.166463 HNRPU 19 10 2
Hs.133294 IQGAP3 8 5 0
N: number of studies (types of cancer) which have available expression data on a tested gene.
Up # or down #: number of cancer types whose expression of the tested gene is up- or down-regulated.
All these genes are significantly consistently up-regulated (P,10
25) in a large majority of cancer types.
doi:10.1371/journal.pone.0001149.t001
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Common Genes in Human Cancers
PLoS ONE | www.plosone.org 4 November 2007 | Issue 11 | e1149cycle checkpoint II and plk3 pathways. We found that many of the
genes within each of pathways were up-regulated in various types of
tumor tissues as compared with normal tissues. The perturbation of
expression of multiple genes within these pathways may be
a common characteristic of neoplastic transformation and pro-
gression in malignant tumors. Therapeutic manipulation of these
pathways may provide a universal strategy for treatment of many
types of cancer. For example, cancer cells often generate energy
through glycolytic fermentation rather than oxidative phosphoryla-
tion.Itispossiblethatthelackofoxidativephosphorylationlimitsthe
production of proapoptotic superoxide. Three enzymes of the 187
gene profile, TPI, PGK1, and ENO1, which are involved in the
glycolytic pathway, were also found to be significantly overexpressed
in the HER-2/neu-positive breast tumors [23]. Overexpression of
these enzymes may well relate to the increased requirements of both
energy and protein synthesis/degradation pathways in the rapidly
growing tumors. This pathway was proposed to be significant in
tumorigenesis more than 70 years by Warburg [24].
The genes identified in our signature could be the prime targets
of cancer therapy and prevention, since they are dysregulated in
many types of cancer. Characterization of these common genes
should provide opportunities for elucidating certain of the more
general mechanisms of cancer initiation and progression. Cancer
gene therapy classically involves delivery of tumor suppressor,
apoptosis-inducing or suicide genes directly into tumor cells. Arrest
of tumor cell proliferation is the ultimate objective of anticancer
therapy. Interestingly, in our data, the identified common genes
that are involved in regulation of cell proliferation are all up-
regulated in different types of tumor tissues (Table S2). These
genes include TTK, SPP1, NME1, NAP1L1, NPM1 and
Table 2. Common down-regulated genes in human malignancies
..................................................................................................................................................
UniGene Gene symbol N Up # Down # UniGene Gene symbol N Up # Down #
Hs.401835 TCEAL2 10 0 8 Hs.306083 LOC91689 8 0 5
Hs.58351 ABCA8 13 0 10 Hs.160953 P53AIP1 8 0 5
Hs.525205 NDRG2 12 0 9 Hs.211252 SLC24A3 8 0 5
Hs.524085 USP2 12 0 9 Hs.163079 TUBAL3 8 0 5
Hs.172755 BRP44L 11 0 8 Hs.389171 PINK1 13 0 8
Hs.22242 ECHDC3 11 0 8 Hs.470887 GULP1 13 1 8
Hs.196952 HLF 19 1 13 Hs.490981 MSRA 13 1 8
Hs.496587 CHRDL1 12 0 8 Hs.476092 CLEC3B 18 0 11
Hs.476319 ECHDC2 12 0 8 Hs.386502 FMO4 18 0 11
Hs.409352 FLJ20701 12 0 8 Hs.137367 ANK2 18 1 11
Hs.103253 PLIN 12 0 8 Hs.212088 EPHX2 18 1 11
Hs.293970 ALDH6A1 18 1 12 Hs.157818 KCNAB1 18 1 11
Hs.390729 ERBB4 17 0 11 Hs.163924 NR3C2 18 1 11
Hs.553502 RORA 17 0 11 Hs.269128 PPP2R1B 18 1 11
Hs.388918 RECK 14 0 9 Hs.40582 CDC14B 15 1 9
Hs.216226 SYNGR1 14 0 9 Hs.438867 FLJ20489 10 1 6
Hs.506357 FAM107A 14 1 9 Hs.224008 FEZ1 17 1 10
Hs.476454 ABHD6 11 0 7 Hs.443789 C6orf60 12 1 7
Hs.519694 C5orf4 11 0 7 Hs.475319 LRRFIP2 12 1 7
Hs.528385 DHRS4 11 0 7 Hs.514713 MPPE1 12 1 7
Hs.47288 TRPM3 11 0 7 Hs.183153 ARL4D 19 1 11
Hs.420830 HIF3A 11 1 7 Hs.642660 C10orf116 19 1 11
Hs.511265 SEMA6D 11 1 7 Hs.495912 DMD 19 1 11
Hs.436657 CLU 19 1 12 Hs.503126 SHANK2 14 1 8
Hs.78482 PALM 16 0 10 Hs.481342 SORBS2 14 1 8
Hs.82318 WASF3 16 0 10 Hs.169441 MAGI1 16 1 9
Hs.268869 ADHFE1 8 0 5 Hs.75652 GSTM5 18 1 10
Hs.34494 AGXT2 8 0 5 Hs.405156 PPAP2B 18 1 10
Hs.249129 CIDEA 8 0 5 Hs.271771 SNCA 18 1 10
Hs.302754 EFCBP1 8 0 5 Hs.181855 CASC5 9 1 5
Hs.521953 EFHC2 8 0 5 Hs.506458 ANKS1B 11 1 6
Hs.200100 Ells1 8 0 5 Hs.445885 KIAA1217 11 1 6
Hs.479703 FLJ21511 8 0 5 Hs.643583 DKFZp667G2110 13 1 7
Hs.500750 HPSE2 8 0 5 Hs.406787 FBXO3 13 1 7
Hs.380929 LDHD 8 0 5 Hs.431498 FOXP1 13 1 7
All these genes are significantly consistently down-regulated (P ,10
25) in a large majority of cancer types.
doi:10.1371/journal.pone.0001149.t002
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Common Genes in Human Cancers
PLoS ONE | www.plosone.org 5 November 2007 | Issue 11 | e1149TNFSF13B. Osteopontin (SPP1) is a gene that regulates cell
proliferation. Many studies have shown that SPP1 is highly
expressed in several malignancies. Abundant secretion of SPP1
acts as a marker for breast and prostrate cancer, osteosarcoma,
glioblastoma, squamous cell carcinoma and melanoma [25]. Cells
from SPP1 knockout mice show impaired colony formation in soft
agar and slower tumor growth in vivo in comparison with tumors in
wild-type mice [26]. In our QRT-PCR analysis, SPP1 was
overexpressed in 18 out of 22 samples from five different types of
tumor tissues (Figure 1). The tissue microarray analysis further
demonstrated that this increased mRNA expression level of SPP1
was significantly correlated with protein level in cancer patients
(Figure 2). Thus, SPP1 may be a promising common target of
cancer therapy and prevention.
BH3-interacting domain death agonist (BID) and clusterin (CLU)
are two other potential therapeutic targets that are involved in
programmed cell death. BID contains only the BH3 domain, which
isrequired for its interactionwith theBcl-2 familyproteins and for its
pro-death activity. BID is susceptible to proteolytic cleavage by
caspases, calpains, Granzyme B and cathepsins [27]. BID is
important to cell death mediated by these proteases and thus is the
sentinel to protease-mediated death signals [28]. Protease-cleaved
BID is able to induce multiple mitochondrial dysfunctions, including
the release of the inter-membrane space proteins, cristae re-
organization, depolarization, permeability transition and generation
of reactive oxygen species. Thus BID is a molecular bridge linking
various peripheral death pathways to the central mitochondria
pathway. Recent studies further indicated that BID may function as
Table 3. QRT-PCR analysis of selected common cancer genes in initial screens
..................................................................................................................................................
Gene
**** Fold Change
* P-value
** Consistency
*** (%)
Breast Lung Prostate Colon Cervical Average
DMD 2447.7 2127.3 24.9 27.9 210.4 2119.7 0.0242 93.33
HLF 2368.7 22.6 22.4 210.5 212.1 290.3 0.0816 84.62
ERBB4 2352.7 24.6 0.2 22.4 224.6 285.1 0.0713 64.29
SEMA6D 2198.6 281.7 20.4 26.7 5.4 260.8 0.0432 78.57
PLIN 2170.1 3.6 0.1 29.1 23.0 241.2 0.0609 69.23
ABCA8 22041.8 256.0 0.5 214.3 242.2 240.9 0.0008 80.00
NDRG2 2161.8 24.7 21.2 25.1 23.3 237.6 0.0318 85.71
FAM107A 216.4 224.9 23.0 26.5 2131.3 236.4 0.0186 100.00
KCNAB1 216.3 297.4 28.1 28.7 216.8 232.1 0.0165 92.31
NR3C2 271.4 229.6 21.7 25.4 223.6 226.6 0.0036 85.71
CLU 249.1 24.3 22.0 23.7 214.8 214.8 0.0215 78.57
HIF3A 223.3 218.7 23.2 27.3 217.7 214.1 0.0000 86.67
TCEAL2 229.5 21.7 23.9 213.1 28.6 210.7 0.0005 86.67
ALDH6A1 27.2 0.7 1.4 22.0 222.8 27.8 0.0119 75.00
RORA 214.6 27.5 1.2 22.1 21.3 25.5 0.0041 81.82
EPHX2 213.7 20.3 0.6 25.2 26.2 25.0 0.0050 60.00
USP2 23.4 20.2 24.6 28.8 24.6 24.6 0.0000 92.86
PPP2R1B 218.2 22.0 20.5 20.6 1.7 23.9 0.0226 66.67
ANK2 24.2 20.8 22.6 25.0 26.7 23.9 0.0000 85.71
SYNGR1 27.6 21.9 21.5 25.2 20.7 23.4 0.0000 92.31
BRP44L 26.9 23.5 9.8 212.9 22.7 23.3 0.0000 86.67
CDC14B 26.3 25.7 21.7 0.6 0.4 22.8 0.0014 76.92
RECK 24.5 22.7 0.2 20.5 20.9 21.7 0.0000 73.33
PGK1 0.1 0.9 0.6 0.1 12.3 3.2 0.1323 61.54
PRC1 1.6 6.2 0.8 20.3 8.7 3.2 0.0369 64.29
BID 0.9 3.7 3.5 20.2 9.1 3.4 0.0003 80.00
CCT5 0.3 8.6 2.5 20.6 6.7 3.7 0.0256 71.43
FEN1 0.0 5.7 1.8 20.5 15.6 4.5 0.0407 73.33
NME1 0.6 25.4 3.6 2.2 6.3 7.6 0.0197 86.67
NUSAP1 2.7 10.2 5.7 0.6 35.8 11.0 0.0042 73.33
ADAM12 25.2 4.9 23.1 23.9 39.7 12.0 0.0084 53.33
SPP1 1.6 53.9 2.4 40.7 232.9 70.8 0.0117 85.71
*Fold change: negative and positive values indicate an increase and decrease in expression level of tumor tissues compared with normal tissues for each gene,
respectively.
**P-value: one tailed Z-test comparing expression difference between normal and tumor groups.
***Consistency: the percentage of paired samples used for QRT-PCR having the same regulation tendency in microarray data.
****Genes marked bold are top ten scoring genes chosen for QRT-PCR analysis in expanded samples.
doi:10.1371/journal.pone.0001149.t003
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Common Genes in Human Cancers
PLoS ONE | www.plosone.org 6 November 2007 | Issue 11 | e1149more than just a proapoptotic killer molecule. BID not only
promotes cell cycle progression into S phase but also involves the
maintenance of genomic stability by engaging at mitotic checkpoints
[27]. This protein has diverse functions that are important to both
the life and death of the cell. A recent study showed that BID
increased in brain tumor, gliomas, prostate cancer, ovarian cancer
and colon cancer [29]. CLU is a sulphated glycoprotein, implicated
in various cell functions involved in carcinogenesis and tumor
progression, including cell cycle regulation, cell adhesion, DNA
repair and apoptosis. Several studies show greatly reduced
expression of CLU in tumors compared with normal tissue,
including testicular tumor, von Hippel-Lindau (pVHL)-defective
renal tumor, esophageal squamous cell carcinoma[30–34]. The
reduction intheoverallCLUlevelappearsbecausethe CLUpositive
stromal compartments of the normal mucosa are lost in tumor [35].
CLU plays a negative role in epithelial cell proliferation and lack of
CLU increases the susceptibility to tumorigenesis after carcinogenic
challenge. The under-expression of CLU was immediately apparent
inhighly malignant MDPR317 prostate adenocarcinoma cells using
laser microdissection technique and serial analysis ofgene expression
[36]. Both our QRT-PCR and tissue microarray analyses confirmed
the upregulation of BID and downregulation of CLU in most of
cancerous tissues (Figure 3).
Stem cells are the very earliest cells of the embryo that divide
and differentiate to form mature organs and tissues. Small
numbers of normal stem cells persist into adulthood and function
to maintain and repair healthy tissues. It has been recently
established that, like normal tissues, human tumors are initiated
Figure 1. QRT-PCR analysis for the selected top ten scoring genes in expanded samples. Fold differences over matched normal controls were
plotted for 21 to 24 tumors from all tested tissues including breast, lung, prostate, colorectal and cervical tumors in duplicate, providing 42 to 48 data
points per gene. The average fold change, p value, consistency of regulation tendency, and numbers of tissues with over or under-expression were
also listed.
doi:10.1371/journal.pone.0001149.g001
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PLoS ONE | www.plosone.org 7 November 2007 | Issue 11 | e1149and maintained by stem cells. Cancer stem cells exist as a minority
population within the tumor and share many genetic and biologic
characteristics of normal stem cells. Some genes overexpressed in
cancer tissues identified in our signature were found highly
expressed in embryonic stem cells. For example, EPRS, NPM1,
STAT1 and LSM4 are higher expressed in human embryonic
stem cell lines compared with human universal RNA [37,38].
CCNB1, FBXO2, NME2, SNRPF, DDX21, SLC38A4, PSMA2,
PSMA3 and AP1S2 are also higher expressed in human
embryonic stem cell lines [37,38], members of these gene families
such as CCNB2, FBXO32, NME1, SNRPB, DDX39, SLC38A1,
PSMA4, PSMA7 and AP1S1 are observed in our signature.
Particularly, two genes in our signature, DNMT1 and TAPBP, are
listed on SuperArray GEArray S Series Human Stem Cell Gene
Array, which is designed to profile the expression of genes known
to be important for the identification, growth and differentiation of
stem cells (Catalog number HS-601.2, Superarray, Frederick, MD;
http://www.superarray.com/home.php). Our gene signature also
includes several genes related to tissue development, such as
regulation of developmental process (FNDC3B, SPP1 and TTL),
embryonic development (ADAM10) and organ development
(NCL, SPP1, SFXN1, BAX, ADAM12, NRP2 and NME1)
(http://fatigo.bioinfo.cnio.es).
In summary, we defined a cancer-type-independent gene
signature predictive of cancer status for a wide variety of human
malignancies. This signature has captured the essential transcrip-
tional transition of normal cell behavior to uncontrolled cell
growth in malignant tumors and thus has significant implications
in cancer diagnostics, prognostics and therapy. These genes should
Figure 2. Immunostaining analysis of SPP1 expression in normal and
tumor tissues. SPP1 positive staining presents in cytoplasm and nuclear
of tumor cells in lung cancer (A, right), breast cancer (B, right), ovary
cancer (C, right), and Colon cancer (D, right) while negative staining in
normal lung (A, left), and ovary (C, left), weak staining in normal breast
(B, left), and colon (D, left).
doi:10.1371/journal.pone.0001149.g002
Figure 3. CLU and BID immunostaining in tumor and normal tissues.
Positive cytoplasmic staining of CLU presents on both tumor and
normal cells in lung, breast, colon, and ovary tissue (A to D). CLU
expression decreased in lung cancer (A, upper level) in comparison with
normal lung (A, lower level). Both normal breast (B, lower level) and
ovary (D, lower level) show middle to strong staining in cytoplasm, and
middle to weak staining in breast (B, upper level) and ovarian cancer (D,
upper level). Much less positive clusterin staining present in both colon
tumor (C, upper level) and normal tissues (C, lower level). BID shows
strong cytoplasmic and nuclear staining in lung cancer (E, upper level)
and weak nuclear staining in normal lung epithelium (E, lower level).
Increased strong nuclear and cytoplasmic staining is seen in breast
tumor (F, upper level) when compared with normal breast tissue (F,
lower level). In colon cancer, BID shows strong cytoplasmic and nuclear
staining in tumor cells (G, upper level), while less positive BID staining
was found in normal colon tissue (G, lower level). Semiquantitative
analysis of CLU and BID immunoreaction in tumors and normal tissues
(H). Most of samples from different types of cancer have strong, high
percentage of BID immunoreaction, and normal tissues only show
middle to low level staining; while CLU tends to down-regulated in
tumors (H). High=score 10–12, middle=score 6–9, and low=score 1–5.
Left column in each panel is at low power (100X) and right column in
each panel is at high power (400X).
doi:10.1371/journal.pone.0001149.g003
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PLoS ONE | www.plosone.org 8 November 2007 | Issue 11 | e1149prove applicable to not only understand the common molecular
mechanism of cancer, and cancer diagnosis, but also serve as
potential molecular targets as well.
MATERIALS AND METHODS
Data collection and processing
Microarray datasets were obtained from public databases. Data
were of two general types, dual channel ratio data corresponding
to spotted cDNA microarrays and single channel intensity data
corresponding to Affymetrix microarrays. Thirty nine studies had
634 normal and 1,552 cancer samples in total (Table S1). All
these previous microarray studies were originally designed for the
identification of differentially expressed genes between normal and
malignant tumor tissues for that specific type of cancer. Pathology
reports were the basis for classify the normal and tumor tissue, and
benign and malignant tumors in these studies. Datasets 1–20
which represent 20 different common cancer types such as
bladder, breast, colon, endometrial, kidney, liver, lung, melanoma,
lymphoma, pancreatic, prostate and thyroid cancer were used to
identify common cancer genes and pathways, and datasets 21–39
were used for extensive validation. The chosen training datasets
were normally larger than validation datasets except several very
recently released datasets. All of the expression values were base-
two log transformed. To facilitate multi-study analysis, Unigene
cluster ID and gene names were assigned to all of the cDNA clones
and Affymetrix probes based on the NCBI Unigene Build 198
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene).
Detection of differentially expressed genes
We used two-sample permutation t test for identifying differentially
expressed genes (DEGs), which was implemented in R package
permax (http://www.r-project.org/), for each of the datasets 1–20.
To obtain the robust results, 10,000 permutations were performed
to calculate an empirical p value in the analysis of DEGs in each
type of cancer.
Common cancer biomarkers
To identify common biomarkers in different types of cancer, we
used a permutation procedure to examine if DEGs (p,0.01) are
statistically consistently up-regulated or down-regulated in differ-
ent types of cancer. Specifically, we first determined how often
a DEG is consistently up-regulated or down-regulated in different
types of cancer in the original datasets. Then, we reshuffled cancer
status (normal and tumor) and created 100,000 replicates for each
type of cancer. In each replicate, we conducted the analysis of
DEGs as described in the section ‘‘Detection of differentially expressed
genes’’, and record the number of cancer types in which a DEG is
consistently up-regulated or down-regulated. Finally, the proba-
bility for observing a common biomarker in different types of
cancer by random chance is calculated as,
p~
P
i 1(ci§n)
N
where N is the number of permutations, n is the number of cancer
types in which a DEG is consistently up-regulated or down-
regulated in the original datasets, and ci is the number of cancer
types in which a DEG is consistently up-regulated or down-
regulated in i-th permutation, i=1,2,….N.
Pathway analysis
Sets of genes that act in concert to carry out a specific function
were also identified in different types of cancer. Gene sets we used
are listed as c2 for curated gene sets in the Molecular Signature
Database (MSigDB, http://www.broad.mit.edu/gsea/msigdb/
msigdb_index.html). We also employed permutation analysis to
examine if DEGs (p,0.01) are statistically significantly enriched in
a given pathway. Specifically, we first record the number of DEGs
in each of 1,687 pathways in original datasets. Then, we randomly
reshuffled cancer status to create 100,000 replicates. In each
replicate, we conducted the analysis of DEGs as described in the
section ‘‘Detection of differentially expressed genes’’ and record the
number of DEGs. The probability for observing the richness of
DEGs in a given pathway by chance is calculated as,
p~
P
i 1(mi§n)
N
where N is the number of permutations, n is the number of DEGs
observed in a given pathway in the original dataset, and mi is the
number of DEGs observed in each randomly permuted replicate,
i=1,2,….20. This analysis was performed separately in each type
of cancer.
Clustering analysis
Hierarchical clustering based on centered Pearson correlation
coefficient algorithm and average linkage method was used to
show the expression patterns of common cancer genes in datasets
21 to 39. The datasets were normalized by standardizing each row
(gene) to mean 0 and variance 1. The clustering analysis was
Table 4. Confirmation of the common gene expression
pattern in independent datasets
......................................................................
Dataset Cancer types NN NT NE Accuracy (%)
21 Colon cancer 12 48 4 93.33
22 Esophageal adenocarcinomas 15 19 0 100.00
23 Gastric Cancer 8 22 1 96.67
24 Glioblastoma 4 31 4 88.57
25 Head neck hypopharyngeal
cancer
4 34 8 78.95
26 Lung cancer 30 57 5 94.25
27 Lung cancer 5 5 0 100.00
28 Lung cancer 19 20 0 100.00
29 Lymphoma 6 21 0 100.00
30 Myeloma 8 17 0 100.00
31 Prostate cancer 6 13 1 94.74
32 Prostate cancer 41 71 19 83.04
33 Testicular germ cell tumors 14 23 1 97.30
34 Testicular germ cell tumors 3 20 4 82.60
35 Thyroid carcinoma 7 7 2 85.71
36 Mesothelioma 9 40 4 91.84
37 Uterine Leiomyomas 5 5 1 90.00
38 Soft Tissue Sarcoma 15 39 1 98.15
39 Multiclass cancer 81 180 39 85.06
Sum / 292 672 94 92.64
NN: number of normal samples; NT: number of tumor samples; NE: number of
errors, that is, number of samples that were falsely clustered; Accuracy (%): NE/
(NN+NT).
doi:10.1371/journal.pone.0001149.t004
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Common Genes in Human Cancers
PLoS ONE | www.plosone.org 9 November 2007 | Issue 11 | e1149Figure 4. Hierarchical clustering of gene-expression profiles for 187 common cancer genes in dataset 39 with mixed cancer types. Normal tissues
were marked black and tumor tissues were marked red. Samples are clustered into three groups: tumor group I composing of 57 tumors and 20
normal tissues, normal group composing of 11 tumors and 53 normal tissues, and tumor group II composing of 112 tumor and 8 normal tissues. All of
central nervous system cancer and most of pancreatic adenocarcinoma were classified into tumor group I, while all of leukemia and most of
lymphomas were classified into tumor group II. The accuracy of classification is 85%.
doi:10.1371/journal.pone.0001149.g004
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PLoS ONE | www.plosone.org 10 November 2007 | Issue 11 | e1149performed by using CLUSTER and TREEVIEW software
(http://rana.lbl.gov/EisenSoftware.htm). Classification accuracy
for each of these datasets was calculated.
QRT-PCR Analysis
Using 15 pairs of tumor and matched adjacent normal tissues from
five cancer types (breast, lung, prostate, colon-recta and cervical
cancer), three pairs for each cancer type, the relative expressions of
32 randomly chosen common cancer genes from the identified
signature gene set were initially screened by QRT-PCR analysis,
as described in a previous study [39]. These frozen tissues were
acquired from Tissue Procurement Core at Washington Univer-
sity Siteman Cancer Center (St. Louis, Missouri, United States).
Primers for the QRT-PCR analysis (Table S4) were designed
using Primer Express software version 2.0 (Applied Biosystems,
Foster City, CA). Amplification of each target gene was performed
with SYBR Green master mix in BIO-RAD Single Color Real-
Time PCR Detection system according to the manufacture
protocols. The control gene b-Actin and target genes were
amplified with equal efficiencies. The method for assessing if two
amplicons have the same efficiency is to look at how DCT
(CT,target–CT,b-Actin, where CT is cycle number at which the
fluorescence signal exceeds background) varies with template
dilution, which is described in detail elsewhere [40]. The fold
change of gene expression in normal tissues relative to tumor
tissues was calculated as 2
2DDCT (DDCT=DCT normal–DCT tumor).
One tailed Z-test was performed to determine statistical
significance between normal and tumor groups. The average fold
change of each gene and the consistency of the regulation
tendency with the microarray data were also calculated. According
to these three characteristics, the ten highest scoring genes were
selected for further QRT-PCR confirmation using 18 matched
tumor and normal samples from breast, lung and cervical cancer
patients, three pairs for each cancer type.
Tissue microarray
Tissue microarray (TMA) slides were purchased from the NCI
Tissue Array Research Program (http://ccr.cancer.gov/tech_
initiatives/tarp/). All samples were formalin-fixed, paraffin-
embedded tissues. Limited demographic and pathology informa-
tion was available at the NCI website (http://ccr.cancer.gov/
tech_initiatives/tarp). The TMA slides contained four tumor types
including colon adenocarcinoma, breast adenocarcinoma, ovary
adenocarcinoma, lung cancer, and normal tissues, each from
a distinct patient. The normal tissues were not paired with the
tumor tissues on the slides. The tissue of origin for all samples was
confirmed by experienced surgical pathologists. Each TMA slide
contained 200 tissue samples of 0.6 mm and was ready for use in
immunohistochemistry, but only among which there were limited
normal tissues. In order to have enough normal tissue samples for
comparison, we obtained additional normal tissue slides from
Tissue Procurment Core at Washington University in St. Louis
School of Medicine according to the approved protocol by
Washington University in St Louis Human Studies Committee,
such that the total number of normal tissues was 65. All slides were
deparaffinized and rehydrated before antigen retrieval which was
applied in microwave for 20 minutes with citrate buffer, pH 6.0.
After blocking in 10% of normal goat serum in PBS, all primary
antibodies were incubated overnight at 4uC, including SPP1
(Novocastra Laboratories, Newcastle, UK, clone 15G12, dilution
1:100), BID (BD Tranduction Laboratories, San Jose, CA, clone 7,
dilution 1:200) and CLU (Upstate Biotech, Lake Placid, NY, clone
41D, dilution 1:1000). The appropriate secondary biotinylated
IgG (1:500) was used, followed by ABC method (Vectastain ABC
Elite Kit, Vector Lab, Burlingame, CA) and diaminobenzidine
(DAB) (Sigma, St. Louis, MO) was used as chromogen. For
negative control, the primary antibody was omitted with normal
serum. The percentage of positive cancer cells was scored on
a semiquantitative scale as 0 (0%), 1 (1–20%), 2 (20–50%), 3 (50–
75%) and 4 (over 75%). Intensity was scored as 1 (weak), 2 (middle)
and 3 (strong). Results were calculated by multiplying the score of
percentage of positive cells (P) by the intensity (I). The maximum
score is 12. The evaluation of immunostaining results was
performed independently by two investigators. Student’s t test
was used to assess the significance of expression difference from
normal and tumor tissues.
SUPPORTING INFORMATION
Figure S1 The immunostaining images of SPP1 in various
cancer tissue microarray. The sections from normal tissues are
shown in box A. Additional sample information was available at
the NCI website (http://ccr.cancer.gov/tech_initiatives/tarp).
Found at: doi:10.1371/journal.pone.0001149.s001 (2.31 MB
PDF)
Figure S2 Three pathways enriched in various cancer types. (A)
glycolysis pathway, (B) cell cycle checkpoint II pathway and (C)
plk3 pathway. Dark red, overexpressed in tumors (p,0.01); light
red, overexpressed in tumors (p.0.01); dark green, under-
expressed in tumors (p,0.01); light green, underexpressed in
tumors (p.0.01); white, missing data.
Found at: doi:10.1371/journal.pone.0001149.s002 (0.61 MB
PDF)
Figure S3 Hierarchical clustering of gene-expression profiles for
187 common cancer genes in datasets 21–38. Normal tissues were
marked black and tumor tissues were marked red. The accuracy of
classification is, on average, 92.64% ranging from 78% to 100%.
Found at: doi:10.1371/journal.pone.0001149.s003 (2.19 MB
PDF)
Figure S4 Hierarchical clustering of gene-expression profiles in
dataset 39 using 28 common cancer genes confirmed by the QRT-
PCR analysis with fold change .3 and consistency .60%.
Samples are also clustered into three groups: tumor group I
composing of 123 tumors and 18 normal tissues, tumor group II
composing of 46 tumor and 24 normal tissues, and normal group
composing of 39 normal tissues and 11 tumors. The accuracy of
classification is 80%.
Found at: doi:10.1371/journal.pone.0001149.s004 (0.15 MB
PDF)
Table S1 Datasets in the integrated gene-expression analyses
Found at: doi:10.1371/journal.pone.0001149.s005 (0.17 MB
DOC)
Table S2 Functional categories of common up- and down-
regulated cancer genes
Found at: doi:10.1371/journal.pone.0001149.s006 (0.07 MB
DOC)
Table S3 A comparison of several signatures in independent
datasets
Found at: doi:10.1371/journal.pone.0001149.s007 (0.03 MB
DOC)
Table S4 Oligonucleotide primers and probes used for real-time
PCR Analysis
Found at: doi:10.1371/journal.pone.0001149.s008 (0.05 MB
DOC)
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